(P041) Clinical Outcomes of Gamma Knife Stereotactic Radiosurgery (GK-SRS) for Painful Trigeminal Neuropathy (TNP)
SRS is both safe and efficacious for PTN. Additionally, prior to treatment, PTN patients who characterize their facial pain as dull and not exacerbated by daily activities are more likely to receive therapeutic benefit, with a mean response time of 1 month.
David Zaenger, MD, M.N. Woodall, MD, Bryan M. Rabatic, PhD, MD, John R. Vender, MD, Waleed F. Mourad, MD, PhD, Joseph Kaminski, MD; Georgia Regents University
PURPOSE: Painful trigeminal neuropathy (PTN) is a rare variant of trigeminal neuralgia (TN) that necessitates prior trigeminal nerve injury, in addition to facial pain. While the evidence supporting the safety and efficacy of Gamma Knife stereotactic radiosurgery (GK-SRS) for medically refractory TN is well established, there is a limited body of literature concerning SRS for medically refractory PTN. We report our long-term clinical outcomes using GK-SRS for medically refractory PTN.
METHODS: This is a single-institution retrospective study of 320 patients treated with GK-SRS for TN between 2000 and 2013. From this cohort, 20 XRT-naive patients with PTN were identified. All patients failed initial treatment with medications, and seven (35%) received other invasive treatment (eg, microvascular decompression, rhizotomy) prior to SRS. All patients underwent frame-based single-fraction GK-SRS. Mean age was 61 years (range: 38–80 yr), and 75% of patients were female. Fifteen patients (80%) were Caucasian, four (15%) were African American, and one (5%) was Asian. Mean dose was 80 Gy (range: 80–90 Gy) to the 100% isodose line in a single fraction to the root entry zone of the involved trigeminal nerve (2–3 mm from the anterolateral surface of the pons). Complete response (CR), near-CR, and partial response (PR) were defined as being pain-free without medication, being pain-free with medication, and having reduced pain with medication, respectively.
RESULTS: With a median follow-up of 20 months (range: 3–70 mo), the overall response was 60%. Specifically, CR, near-CR, and PR rates were 27%, 20%, and 13%, respectively. No response (NR) was seen in 40% of patients, who had persistent, unchanged pain. For the 60% of patients who responded to GK-SRS, the mean time latency from SRS to response was 1 month (range: 0–2 mo). The pattern of pretreatment pain in the responders group was described as being dull rather than sharp compared with nonresponders. Additionally, when compared with the NR group, the CR group was significantly less likely to be exacerbated by daily activities pretreatment (0/4 [0%] vs 5/6 [83%]). No GK-SRS-induced grade ≥ 2 toxicities were reported.
CONCLUSIONS: SRS is both safe and efficacious for PTN. Additionally, prior to treatment, PTN patients who characterize their facial pain as dull and not exacerbated by daily activities are more likely to receive therapeutic benefit, with a mean response time of 1 month.
Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
